REGN · Regeneron Pharmaceuticals, Inc. · Share Buybacks
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-02-01 | $3,000,000,000 | $2,200,000,000 | 2026-09-30 | — | 8-K , filed 2026-10-30 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-09-30 YTD | $2,363,400,000 | 10-Q, filed 2026-10-30 | ||
| 2025-12-31 | $3,438,600,000 | 10-K, filed 2026-02-04 | ||
| 2024-12-31 | $2,603,300,000 | 10-K, filed 2026-02-04 | ||
| 2023-12-31 | $2,235,000,000 | 10-K, filed 2026-02-04 | ||
| 2022-12-31 | $2,082,800,000 | 10-K, filed 2025-02-05 | ||
| 2021-12-31 | $1,645,400,000 | 10-K, filed 2024-02-05 | ||
| 2020-12-31 | $5,846,800,000 | 10-K, filed 2023-02-06 | ||
| 2019-12-31 | $275,900,000 | 10-K, filed 2022-02-07 | ||
| 2018-12-31 | $4,400,000 | 10-K, filed 2021-02-08 | ||